Delivery Order SPE2DB20D1004-SPE2DB23FE8L3
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, with a ceiling value of $1,119.48, is for the delivery of Eletriptan HBR 40 mg tablets. The contract has an ultimate completion date of September 21, 2023, and is a firm fixed-price delivery order. The contract was awarded on September 20, 2023, and is not designated with a set-aside. Amerisourcebergen Drug Corp is a major...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,419.27 firm fixed-price delivery order is for the supply of eletriptan HBR 20 mg tablets. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product eletriptan hydrobromide 40 mg tablets. The $1,617.17 fixed-price delivery order was placed by the Defense Logistics Agency (DLA), a defense agency of the U.S. government. Amerisourcebergen, a major pharmaceutical distributor, holds a single-award Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop Support Medical through 2025. This...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) for the delivery of Eletriptan HBR 40 mg tablets. The contract has a firm fixed price of $1,506.34 and a completion date of April 14, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle...
- This federal contract award, valued at $6,008.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4562729691 - Eletriptan HBR 20 mg Tablet UD 6s, with a completion date of November 7, 2023. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that has established itself as...
- This federal contract award, valued at $1,155.11, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ELETRIPTAN HBR 20 MG TABLET UD 6S, a pharmaceutical product, and has an ultimate completion date of February 6, 2024. This is a firm fixed-price delivery order contract, and there is no set-aside designation indicated. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of ELETRIPTAN HBR 40 MG TABLET UD 6S. The contract has a firm fixed price of $2,922.56 and a completion date of January 8, 2025. The contract is a delivery order, and there is no set-aside designation. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, including the...
- This federal contract award is for the delivery of 4,564,296,767 units of Eletriptan HBR 40 mg tablets to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense. The fixed-price, firm-fixed-price contract was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, on April 16, 2024 with a completion date of April 17, 2024. The contract has a ceiling value of $1,118.79 and does not have a set-aside designation....
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,638.84, is for the delivery of ELETRIPTAN HBR 40 MG TABLET UD 6S, a medication. The contract has a final completion date of May 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, is for the provision of ELETRIPTAN HBR 40 MG TABLET UD 6S. The contract, valued at $3,546.38, is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA). Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB23FE8L3Delivery Order
This federal contract award, valued at $1,181.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of 4559037029 - Eletriptan HBR 40 MG Tablet UD 6S, with a completion date of November 9, 2022. It is a Firm Fixed Price contract, with no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization registered in the System for Award Management (SAM.gov). The company has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 11/8/22 |